Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is an alpha‑1 adrenergic agonist. By stimulating alpha‑1 receptors on the dilator pupillae muscle, it causes contraction of this muscle, leading to pupil dilation. When combined with tropicamide, the overall effect is a rapid and sustained mydriasis suitable for ophthalmic use.

The dosing regimen for Mydriasert is determined by the prescribing ophthalmologist based on the specific clinical need, patient age, and ocular condition. The prescriber will specify the number of drops, timing, and any repeat applications required for the intended procedure.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate each case individually and discuss possible risks with the patient.

To order Mydriasert, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Mydriasert combines an alpha‑1 agonist (phenylephrine) with an antimuscarinic (tropicamide), providing both dilator and cycloplegic effects in a single formulation. Compared with single‑agent drops such as phenylephrine alone or tropicamide alone, Mydriasert often achieves faster and more complete dilation, reducing the need for multiple applications.

Mydriasert should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture. Do not freeze the product, and keep the cap tightly closed when not in use to maintain sterility.

Mydriasert is applied topically to the eye as a sterile ophthalmic solution. The prescriber will instruct the patient or healthcare professional on the number of drops per eye, the interval between doses, and any necessary precautions such as avoiding contact with other surfaces.

The most serious risks include acute angle‑closure glaucoma, severe allergic reactions (including anaphylaxis), and significant increases in intra‑ocular pressure that could threaten vision. Patients should be monitored closely for signs of pain, visual changes, or systemic hypertension after administration.

Mydriasert is contraindicated in patients with known hypersensitivity to phenylephrine, tropicamide, or any excipients in the formulation. It should also be avoided in individuals with narrow‑angle or closed‑angle glaucoma, uncontrolled hypertension, or severe cardiovascular disease unless directed by a specialist.